tac-1

Amsilarotene (TAC101) inhibits the phosphorylation of retinoblastoma gene product (RB) and increases the presence of 2 cyclin-dependent kinases (CDK) inhibitors resulting in cell cycle arrest. This agent also causes a cytotoxic decline in the thymidylate synthase and cyclin A expression.

FC9402 is a potent and selective inhibitor of sulfide quinone oxidoreductase (SQOR), which can be used to regulate cardiovascular conditions by reducing cardiomyocyte hypertrophy and left ventricle (LV) fibrosis induced by TAC [1].

CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7. CXCR7 antagonist-1 prevents tumor cell proliferation and tumor formation and can be used in studies about inflammatory diseases.

CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits the binding of SDF-1 chemokine (also known as CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. Hydrochloride can be used for the prevention of tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases.

Camidanlumab (HuMax-TAC), a CD25 monoclonal antibody, selectively binds to the cell-surface antigen CD25, prevalent on numerous hematological tumors but minimally present on normal tissues. This specificity facilitates its use in developing antibody-drug conjugates (ADCs) aimed at treating diseases such as lymphoma and leukemia [1].

Vopikitug, a human IgG1-kappa monoclonal antibody targeting the IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25), exhibits antineoplastic activity [1].